Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (<scp>KRd</scp>) versus bortezomib, lenalidomide, and dexamethasone (<scp>VRd</scp>) in newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis

Published:2024-04-12 Issue:7 Volume:99 Page:1411-1414
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Costa Bruno Almeida¹²^ORCID,Costa Thomaz Alexandre³^ORCID,Pak Kevin¹^ORCID,Patel Aesha¹^ORCID,Felix Nicole⁴^ORCID,Mouhieddine Tarek H.⁵^ORCID,Richter Joshua⁵^ORCID

Affiliation:

1. Department of Medicine Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai New York New York USA

2. Department of Medicine Memorial Sloan Kettering Cancer New York New York USA

3. Department of Medicine Federal University of Ceará Fortaleza Brazil

4. Department of Medicine Federal University of Campina Grande Campina Grande Brazil

5. Division of Hematology and Medical Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27314

Reference6 articles.

1. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP